Clinical Trial Screening Visit: What to Expect

Between "I am interested" and "I am enrolled" sits screening: a set of visits, tests, and record checks whose only job is to find out whether you qualify.

Screening is not treatment, and not a promise of treatment. That changes how you plan the next few weeks.

People are surprised to sign a consent form before anyone knows if they qualify. The U.S. Food and Drug Administration (FDA) requires it. Its guidance states that "informed consent must be obtained prior to initiation of any clinical procedures that are performed solely for the purpose of determining eligibility for research."

The line FDA draws is about purpose. A scan or blood test being done for your medical care anyway can be used to check eligibility without a separate consent. A test done only because the study needs it requires consent first.

FDA also tells physician-investigators to "take extra care to clarify with their patient-subjects why certain tests are being conducted." If your own oncologist is also the investigator, ask directly: is this test for my care, for the study, or both?

The institutional review board, the committee that approves and oversees the research, should receive "a written outline of the screening procedure to be followed and how consent for screening will be obtained." So a documented plan exists, and you can ask what it says.

Consent is not always a signature. FDA says that where the screening tests carry no more than minimal risk, the board may decide a consent document does not have to be signed. Either way, the conversation comes first.

Consenting to screening does not enroll you. It permits the screening.

The National Cancer Institute (NCI) describes the sequence. First comes a pre-screening conversation covering "the goals of the trial" and "the drug being tested, how it works, and what is known about its side effects." Then the consent discussion. Then screening itself, where "the study team will review your medical history and conduct any necessary tests to make sure you meet all the requirements."

In practice that usually means several of these:

• A full history and physical examination.
• Blood work, often including counts, kidney function, and liver function.
• Fresh baseline imaging. Studies require the measurements to be taken in a defined way, so scans from another hospital are often repeated.
• Heart testing, if the drug can affect the heart.
• Pregnancy testing where relevant, and a discussion of contraception requirements.
• A tumor tissue sample. If eligibility depends on a gene change in your cancer, the team needs tissue to test. Ask whether stored tissue from an old biopsy will do, or whether a new biopsy is required.

Ask for the whole list in writing, with how many trips each item needs. That sheet is the most useful thing to leave the first visit with.

Every protocol, the detailed plan a trial follows, "clearly states who can or cannot join the trial." Criteria fall into inclusion, meaning what you must have, and exclusion, meaning what rules you out.

NCI says these criteria can involve health status, medical history, family medical history, risk factors, age, previous treatment, and the "tumor's genetic changes." They are not arbitrary. They exist so "the results are due to the intervention or drug being tested."

Read the exclusion list first, because it fails faster. But do not disqualify yourself on a close call. A borderline lab value may sit inside range on a repeat draw, and some protocols allow documented exceptions. The coordinator knows which is which.

Two things stretch the calendar.

The first is the tests. Scheduling a scan, a heart test, and a biopsy in order takes time, and results must return before anyone can say yes.

The second is a washout period, meaning a required break between your last treatment and your first study dose. Protocols set these so that the earlier drug is out of the picture when the study drug begins. Ask how long yours is, when the clock started, and whether anything can be given during the gap.

Then ask the question underneath both: how long can my cancer safely wait while this happens? If the honest answer is "not long," that changes which trials are worth screening for.

Not everyone who signs a screening consent goes on to enroll. A lab drifts out of range, a scan shows something new, tissue testing comes back without the required marker.

This is common and not a personal failing. Ask three things before you start: if I do not qualify, do you keep my results, will you tell me what they showed, and is there another trial here I should try?

The same split applies as elsewhere in a trial. Tests you would have had anyway are routine patient care costs. Tests done only because the study needs data are research costs.

Medicare's trial coverage rule is explicit that it will not pay for "items and services provided solely to satisfy data collection and analysis needs and that are not used in the direct clinical management." Sponsors normally cover those.

Get a written answer for the screening tests. This is where surprise bills show up, especially if screening ends without enrollment.

NCI describes the research team as "made up of doctors, nurses, and research assistants." Two roles matter most during screening.

The principal investigator "supervises all aspects of a clinical trial" and is responsible for the informed consent process. The research nurse "educates staff, participants, and referring health care providers" and usually answers your questions between visits.

Get a name, a direct number, and an email for your screening coordinator.

• A written treatment summary: diagnosis in pathology wording, stage, every prior drug with start and stop dates and why each stopped.
• Radiation records, including sites and doses.
• Surgical history and dates.
• Recent scan reports, and the images on a disc if possible.
• Any biomarker or genomic test reports.
• A complete medicine list, including over-the-counter drugs, vitamins, herbal products, and cannabis. These can affect eligibility and can interact with study drugs, so leaving one off is not harmless.
• The name and number of your regular oncologist.

• Which are done for my care, and which only for the study?
• What is the washout period, and when does it start?
• Is stored tumor tissue enough, or do I need a new biopsy?
• What would make me a screen failure, and how likely is that in my case?
• If I qualify, how soon would treatment start?

• U.S. Food and Drug Administration — Screening Tests Prior to Study Enrollment.
• National Cancer Institute — What to Expect During a Clinical Trial.
• National Cancer Institute — How Do Clinical Trials Work?.
• National Cancer Institute — Taking Part in Cancer Treatment Research Studies.
• Centers for Medicare & Medicaid Services — NCD 310.1, Routine Costs in Clinical Trials.

Helpful next pages include Joining a Clinical Trial: Risks and Questions, What Are Eligibility Criteria for Clinical Trials?, What Is Informed Consent in a Clinical Trial?, How Biomarker Testing Connects to Clinical Trials, Clinical Trial Scan Schedule: What to Ask, Decentralized Clinical Trials: What Patients Should Ask.